4-IN THE LUNG RUN: towards INdividually tailored INvitations, screening INtervals, and INtegrated co-morbidity reducing strategies in lung cancer screening

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON27422

Enrollment

26000

Registered

2021-08-31

Start date

2020-01-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

CT lung cancer screening

Eligibility

Inclusion criteria

Inclusion criteria: men and women, aged 60-79 years, at high risk for developing lung cancer, who gave written informed consent to participate

Exclusion criteria

Exclusion criteria: 1. Recent abnormal pulmonary findings under work-up of standard care. 2: Having had a computed tomography scan of the thorax <1 year before potential entry into the study. 3: Current or prior history of lung cancer. 4: Inability to provide signed informed consent. 5: Insufficient understanding of the languages in which trial information is available. 6: Unable to be followed-up for at least 5-years. 7: Body weight over 140 kg

Design outcomes

Primary

Measure	Time frame
stage I-II lung cancer incidence	—

Secondary

Measure	Time frame
1: The rate of (late stage) interval cancers in each arm. 2: The rates of informed uptake of (sub-group) participants 3: The rates of smoking cessation within individuals in the trial smoking at the baseline screening. 4: The crude costs and cost-effectiveness of each arms. 5: Policies for risk-stratification through biomarkers. 6: The external validation and update/extension of various lung cancer risk-prediction models in 4-IN-THE-LUNG-RUN 7: Guidelines and training programmes for CT screening and pulmonary nodule management. 8: Overview of sex and gender differences in lung cancer risk and screening effectiveness. 9: Overview of SES and gender representativeness within the trial. 10: Comparison and merging of results with other ongoing European studies.	—

Measure

Time frame

1: The rate of (late stage) interval cancers in each arm. 2: The rates of informed uptake of (sub-group) participants 3: The rates of smoking cessation within individuals in the trial smoking at the baseline screening. 4: The crude costs and cost-effectiveness of each arms. 5: Policies for risk-stratification through biomarkers. 6: The external validation and update/extension of various lung cancer risk-prediction models in 4-IN-THE-LUNG-RUN 7: Guidelines and training programmes for CT screening and pulmonary nodule management. 8: Overview of sex and gender differences in lung cancer risk and screening effectiveness. 9: Overview of SES and gender representativeness within the trial. 10: Comparison and merging of results with other ongoing European studies.

—

Contacts

Public ContactCarlijn van der Aalst

ErasmusMC

c.vanderaalst@erasmusmc.nl0031-10-70343446

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)